secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001127537-22-000048
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q3 revenue $13.5M, cuts FY guidance to $51.5-52.5M; extends credit line to 2027
--------------------------------------------------------------------------------

- Q3 revenue $13.5M (+2% YoY, +7% constant currency); US $8.4M (+22%), intl $5.1M (-20%).
- Net loss $14.2M ($0.38/sh) vs $10.2M ($0.28) in Q3 2021; gross margin 75% vs 73%.
- FY2022 revenue guidance cut to $51.5-52.5M from $55-60M; opex guidance lowered to $98-100M.
- Extended loan with CIBC: maturity to Oct 2027, new $20M tranche, 24-month interest-only period.
- Japan MHLW agreed to approve Zephyr Valves; AeriSeal data may expand treatable patient pool.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/0001127537-22-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/lung-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001127537-22-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer